barrigel

What barrigel does

Barrigel is a medical device product brand owned by Teleflex Incorporated (NYSE: TFX) that manufactures and markets the first and only hyaluronic acid-based rectal spacer for prostate cancer radiation therapy. Its core product is built on the NASHA (Non-Animal Stabilized Hyaluronic Acid) platform—a non-animal, viscoelastic, biodegradable gel that is injected between the prostate and rectum prior to radiation treatment to reduce rectal radiation exposure and associated side effects. The gel's key technical differentiator is that it is sculptable, allowing the implanting physician to control shape, layer, and placement in real time under transrectal ultrasound (TRUS) guidance, in contrast to non-sculptable PEG hydrogel alternatives.

Barrigel received FDA 510(k) clearance in May 2022 and pivotal trial results were published in JAMA Oncology in 2023, with 98.5% of patients achieving at least 25% rectal dose reduction, zero Barrigel-related adverse events, and zero implant migrations reported. The product has been used in over 60,000 prostate cancer patients as of January 2025. It is indicated for temporarily positioning the anterior rectal wall away from the prostate during external beam radiotherapy or brachytherapy for T1-T3b prostate cancer.

The company generates revenue through direct hardware sales of the Barrigel device to healthcare providers (radiation oncologists, urologists, hospitals, and outpatient clinics) via Teleflex's specialized sales force and field territory managers. Distribution is global, with active operations in the United States, Japan, and Australia/New Zealand. Physician adoption is gated by a mandatory Barrigel Training Program including online modules, live case training, and peer consultations. Reimbursement is handled through standard medical billing channels (CMS and commercial payers), with a 2026 reimbursement guide in market. In 2026, Teleflex announced a definitive agreement to divest its Interventional Urology portfolio—including Barrigel, UroLift, Deflux, and Solesta—to Intersurgical, with closing expected in the second half of 2026.

Name

barrigel

Legal name

Barrigel (Teleflex Incorporated)

Website

https://barrigel.com

Company type

Private

Founded year

2022

Operating status

Operating

Short description

Barrigel, a Teleflex product brand, makes the first and only sculptable hyaluronic acid rectal spacer used to protect the rectum during prostate cancer radiation therapy, sold to radiation oncologists and urologists across the US, Japan, and ANZ.

Ownership category

akta.pro rank

Product category

Radiotherapy Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

Keywords

• Rectal spacer device
• Prostate cancer treatment
• Radiation protection
• Hyaluronic acid gel
• Urology medical device

Headquarters

HQ city

Pleasanton

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales - Barrigel Rectal Spacer: Barrigel generates revenue through the sale of its hyaluronic acid rectal spacer to healthcare providers (hospitals, outpatient clinics, urology/radiation oncology practices) who use it during prostate cancer radiation therapy procedures. The product is sold to physicians who perform the spacing procedure, with billing typically handled through medical facility reimbursement channels.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Barrigel manufactures and sells a sculptable, Non-Animal Stabilized Hyaluronic Acid (NASHA) rectal spacer that is injected between the prostate and rectum prior to prostate cancer radiation therapy. The device temporarily creates a physical barrier that moves the anterior rectal wall away from the radiation field, reducing rectal dose and associated side effects. It is sold to radiation oncologists, urologists, hospitals, and outpatient cancer centers that treat prostate cancer patients with external beam radiotherapy or brachytherapy.

Product overview

Barrigel offers a focused medical device portfolio centered on the Barrigel Hyaluronic Acid Rectal Spacer—the first and only sculptable, NASHA-based rectal spacer for prostate cancer radiation therapy. The product provides physician-controlled, anatomically personalized spacing between the prostate and rectum, clinically proven to reduce rectal radiation exposure and associated side effects. Barrigel also provides supporting patient resources including the Patient Implant Card for post-procedure identification during medical imaging.

Differentiator

Problem solved

Functional benefit

Brands

• Barrigel Hyaluronic Acid Rectal Spacer: A sculptable hyaluronic acid rectal spacer designed to protect the rectum during prostate cancer radiation therapy by creating space between the prostate and rectum

Products and services

• Barrigel Hyaluronic Acid Rectal Spacer The first and only hyaluronic acid (NASHA-based) rectal spacer that is sculptable and physician-controlled. It is temporarily positioned between the prostate and rectum during prostate cancer radiation therapy to reduce radiation dose to the anterior rectal wall, minimizing rectal side effects. Designed for radiation oncologists, urologists, hospitals, and outpatient cancer centers treating T1-T3b prostate cancer patients.
• Barrigel Patient Implant Card A patient identification card provided after the Barrigel procedure, showing how the spacer may appear on medical imaging systems for future medical appointments. It is a patient resource supporting the core Barrigel rectal spacer product.

Quantifiable outcome

• 98.5% of patients achieved at least 25% reduction in rectal V54 Gy (average 85% dose reduction)
• +6 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Accuray: Developer of CyberKnife and TomoTherapy radiation therapy systems used in prostate cancer treatment. Broad incumbent in radiation oncology whose installed base interacts with rectal spacer products like Barrigel.
• Elekta: Global provider of radiation therapy equipment, treatment planning software, and related oncology solutions. Indirectly comparable as the broader ecosystem player whose linear accelerators deliver the radiation that Barrigel spacers protect against; potential bundling competitor.
• Theragenics: Manufacturer of brachytherapy seeds and other radiation oncology products. Comparable as a radiation-oncology-focused medical device company serving urology and radiation oncology customers that Barrigel also targets.
• Varian Medical Systems (Siemens Healthineers): Leading manufacturer of radiation oncology hardware (linear accelerators, proton therapy) and software, now part of Siemens Healthineers. Adjacent incumbent whose radiation delivery systems define the clinical setting in which Barrigel is used.

Others

• Galderma: Owner of the NASHA (Non-Animal Stabilized Hyaluronic Acid) trademark and broader aesthetics/dermatology platform. Connected to Barrigel through the underlying NASHA technology platform that has been used in 50M+ procedures.
• Intersurgical: Pending acquirer of Teleflex's Interventional Urology portfolio (including Barrigel, UroLift, Deflux, Solesta) expected to close H2 2026. Directly relevant as Barrigel's next strategic owner and commercialization partner.
• Teleflex Incorporated: Current parent company of Barrigel through its Interventional Urology business unit (pending divestiture to Intersurgical in H2 2026). Directly related as the strategic owner and distributor of the Barrigel product line.

Emerging players

• BioProtect: Developer of the BioProtect Balloon Implant System, a biodegradable spacer for prostate radiation therapy. Competes in the same rectal-protection category as Barrigel with an alternative technology approach, addressing overlapping radiation oncologist customers.

Direct peers

• Augmenix: Original developer of the SpaceOAR hydrogel rectal spacer (acquired by Boston Scientific). Directly comparable as a rectal-spacer-focused company in the prostate radiation therapy space, competing head-to-head with Barrigel.
• Boston Scientific: Maker of SpaceOAR Hydrogel, the leading PEG-hydrogel-based rectal spacer used in prostate cancer radiation therapy. Direct competitor to Barrigel in the same clinical indication, serving the same radiation oncologist and urologist customer base with a similar procedural medical device.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Barrigel_spacer
• YouTubeyoutube.com/channel/UCDQFibw94yHr1RANeLCtYmA
• Facebookfacebook.com/Barrigel
• LinkedInlinkedin.com/showcase/barrigel

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about barrigel